You are wrong.
First, comparing the bespoke, groundbreaking DCVax platform to a standardized, one-size-fits-all drug is flawed. They are worlds apart and cannot be assessed by the same criteria. It's like trying to wear a glove that just doesn’t fit.
Second, it seems you've overlooked the potential of DCVax to become the universal treatment for all tumor-based cancers.
Third, considering DCVax’s highly personalized and effective nature, wouldn't a franchise model be more advantageous? It could foster much more competition, benefiting patients, the industry, shareholders, and NWBO itself, rather than letting a single pharmaceutical giant monopolize it.
Market Data 
Markets 
AI
